PMID- 33124592 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220417 IS - 1738-1088 (Print) IS - 2093-4327 (Electronic) IS - 1738-1088 (Linking) VI - 18 IP - 4 DP - 2020 Nov 30 TI - Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar Disorder. PG - 599-606 LID - 10.9758/cpn.2020.18.4.599 [doi] AB - OBJECTIVE: : Several evidence-based practice guidelines have been developed to better treat bipolar disorder. However, the articles cited in these guidelines were based on clinical or basic studies with specific conditional settings and were not sufficiently based on real-world clinical practice. In particular, there was little information on the doses of mood stabilizers. METHODS: The MUlticenter treatment SUrvey on BIpolar disorder in Japanese psychiatric clinics (MUSUBI) is a study conducted to accumulate evidence on the real-world practical treatment of bipolar disorder. The questionnaire included patient characteristics such as comorbidities, mental status, treatment period, Global Assessment of Functioning (GAF) score, and details of pharmacological treatment. RESULTS: Most patients received mood stabilizers such as lithium (n = 1,317), valproic acid (n = 808), carbamazepine (n = 136), and lamotrigine (n = 665). The dose of lithium was correlated with age, body weight, number of episodes, depression and GAF. The dose of valproic acid was correlated with body weight, number of episodes, presence of a rapid cycle and GAF. The dose of carbamazepine was correlated with age, mania, and the presence of a rapid cycle. The dose of lamotrigine was correlated with the number of episodes, depression, mania, psychotic features, and the presence of a rapid cycle. Doses of coadministered mood stabilizers were significantly correlated, except for the combination of valproic acid and lamotrigine. CONCLUSION: The dose of mood stabilizers was selectively administered based on several factors, such as age, body composition, current mood status and functioning. Further prospective studies are required to confirm these findings. FAU - Yasui-Furukori, Norio AU - Yasui-Furukori N AUID- ORCID: 0000-0002-4414-3770 AD - Department of Psychiatry, Dokkyo Medical University, School of Medicine, Tochigi, Japan. AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. FAU - Adachi, Naoto AU - Adachi N AUID- ORCID: 0000-0001-8376-4900 AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Kubota, Yukihisa AU - Kubota Y AUID- ORCID: 0000-0002-9837-6799 AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Azekawa, Takaharu AU - Azekawa T AUID- ORCID: 0000-0003-4294-4600 AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Goto, Eiichiro AU - Goto E AUID- ORCID: 0000-0001-8087-4549 AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Edagawa, Koji AU - Edagawa K AUID- ORCID: 0000-0003-1970-0042 AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Katsumoto, Eiichi AU - Katsumoto E AUID- ORCID: 0000-0001-9417-4391 AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Hongo, Seiji AU - Hongo S AUID- ORCID: 0000-0002-5997-8906 AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Ueda, Hitoshi AU - Ueda H AUID- ORCID: 0000-0001-8950-2872 AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Miki, Kazuhira AU - Miki K AUID- ORCID: 0000-0003-3056-8038 AD - The Japanese Association of Neuro-Psychiatric Clinics, Tokyo, Japan. FAU - Kato, Masaki AU - Kato M AUID- ORCID: 0000-0001-6727-7272 AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Kansai Medical University, Hirakata, Japan. FAU - Yoshimura, Reiji AU - Yoshimura R AUID- ORCID: 0000-0002-7637-5576 AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan. FAU - Nakagawa, Atsuo AU - Nakagawa A AUID- ORCID: 0000-0002-2294-2571 AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Keio University School of Medicine, Minato, Japan. FAU - Kikuchi, Toshiaki AU - Kikuchi T AUID- ORCID: 0000-0003-1025-8796 AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Keio University School of Medicine, Minato, Japan. FAU - Tsuboi, Takashi AU - Tsuboi T AUID- ORCID: 0000-0002-8253-8888 AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Kyorin University School of Medicine, Mitaka, Japan. FAU - Watanabe, Koichiro AU - Watanabe K AUID- ORCID: 0000-0002-0736-7070 AD - The Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. AD - Department of Neuropsychiatry, Kyorin University School of Medicine, Mitaka, Japan. FAU - Shimoda, Kazutaka AU - Shimoda K AUID- ORCID: 0000-0002-9663-6243 AD - Department of Psychiatry, Dokkyo Medical University, School of Medicine, Tochigi, Japan. LA - eng PT - Journal Article PL - Korea (South) TA - Clin Psychopharmacol Neurosci JT - Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology JID - 101207332 PMC - PMC7609211 OTO - NOTNLM OT - Bipolar disorder OT - Dose. OT - Mood stabilizers OT - Nationwide study OT - Real world COIS- Conflicts of Interest Dr. Yasui-Furukori has received grant/research support or honoraria from and been on the speakers of Dainippon-Sumitomo Pharma, Mochida Pharmaceutical, MSD, and Otsuka Pharmaceutical. Dr. Shimoda has received research support from Novartis Pharma, Dainippon Sumitomo Pharma, Astellas Pharma, Meiji Seika Pharma, Eisai, Pfizer, Otsuka Pharmaceutical, Daiichi Sankyo, and Takeda Pharmaceutical, and honoraria from Eisai, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Meiji Seika Pharma, Janssen Pharmaceutical, Shionogi, Dainippon Sumitomo Pharma, Daiichi Sankyo, and Pfizer. Dr. Yoshimura has received speaker's honoraria from Eli Lilly, Janssen, Dainippon Sumitomo, Otsuka, Meiji, Pfizer and Shionogi. Dr. Kato has received grant funding from Japan Society for the Promotion of Science, SENSHIN Medical Research Foundation and Japan Research Foundation for Clinical Pharmacology, and speaker's honoraria from Dainippon-Sumitomo Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., GlaxoSmithkline, Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical and Ono Pharmaceutical. Dr. Azekawa has received speaker's honoraria from Eli Lilly, Otsuka Pharmaceutical, and Pfizer. Dr. Ueda has received manuscript fees or speaker's honoraria from Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Yoshitomi Yakuhin. Dr. Edagawa has received speaker's honoraria from Eli Lilly, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Kyowa and Yoshitomi Yakuhin. Dr. Katsumoto has received speaker's honoraria from Daiichi Sankyo, Eisai, Eli Lilly, Janssen Pharmaceutical, Kyowa Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, UCB. Dr. Kubota has received consultant fees from Pfizer and Meiji-Seika Pharma and speaker's honoraria from Meiji-Seika Pharma, Eli Lilly, Janssen Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Yoshitomi Yakuhin, Otsuka Pharmaceutical, and Eisai. Dr. Goto has received manuscript fees or speaker's honoraria from Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma. Dr. Hongo has received manuscript fees or speaker's honoraria from Eli Lilly, Janssen Pharmaceutical, Kyowa Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Dainippon Pharma, and Yoshitomi Yakuhin. Dr. Tsuboi has received consultant fees from Pfizer and speaker's honoraria from Eli Lilly, Meiji-Seika Pharma, MSD, Janssen Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Yoshitomi Yakuhin, Mochida Pharmaceutical, Otsuka Pharmaceutical, Kyowa Pharmaceutical, and Takeda Pharmaceutical. Dr. Nakagawa has received lecture fees from Pfizer, Eli Lilly, Otsuka, Janssen Pharmaceutical, Mitsubishi Tanabe, Mochida, Dainippon Sumitomo and NTT Docomo, and participated in an advisory board for Takeda, Meiji Seika and Tsumura. Dr. Kikuchi has received consultant fees from Takeda Pharmaceutical and Center for Cognitive Behavioral Therapy and Training. Dr. Watanabe has received manuscript fees or speaker's honoraria from Daiichi Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Kyowa Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Dainippon Pharma, Takeda Pharma-ceutical, Yoshitomi Yakuhin, and has received research/grant support from Astellas Pharma, Daiichi Sankyo, Eisai, MSD, Mitsubishi Tanabe Pharma, Meiji Seika Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Dainippon Pharma, and is a consultant of Eisai, Eli Lilly, Kyowa Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Taisho Toyama Pharma-ceutical, and Takeda Pharmaceutical. EDAT- 2020/10/31 06:00 MHDA- 2020/10/31 06:01 PMCR- 2020/11/30 CRDT- 2020/10/30 08:38 PHST- 2020/05/20 00:00 [received] PHST- 2020/06/05 00:00 [accepted] PHST- 2020/10/30 08:38 [entrez] PHST- 2020/10/31 06:00 [pubmed] PHST- 2020/10/31 06:01 [medline] PHST- 2020/11/30 00:00 [pmc-release] AID - cpn.2020.18.4.599 [pii] AID - CPN-18-599 [pii] AID - 10.9758/cpn.2020.18.4.599 [doi] PST - ppublish SO - Clin Psychopharmacol Neurosci. 2020 Nov 30;18(4):599-606. doi: 10.9758/cpn.2020.18.4.599.